Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Health Literacy and Unmet Needs in Patients With Multiple Sclerosis: A Cross-Sectional Study.

Journal of clinical nursing·2026
Same author

A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Naïve Patients and Switchers in a Multicenter Cohort.

Drugs - real world outcomes·2026
Same author

Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability.

Neurology·2026
Same author

Reduced Childhood Outdoor Exposure Raises Pediatric Multiple Sclerosis (PedMS) Risk.

Neurology and therapy·2026

Related Experiment Video

Updated: Sep 20, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K

Interrogating large multiple sclerosis registries and databases: what information can be gained?

Maria Trojano1, Tomas Kalincik2,3, Pietro Iaffaldano1

  • 1Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari Aldo Moro, Bari, Italy.

Current Opinion in Neurology
|June 8, 2022
PubMed
Summary
This summary is machine-generated.

Real-world studies show early high-efficacy therapies benefit multiple sclerosis (MS) patients, especially children. Data-driven definitions improve identifying secondary progressive MS (SPMS).

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.6K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.2K

Related Experiment Videos

Last Updated: Sep 20, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.6K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.2K

Area of Science:

  • Neurology
  • Real-world evidence
  • Multiple Sclerosis (MS)

Background:

  • Understanding multiple sclerosis (MS) natural history and therapeutics is advancing.
  • Many questions regarding MS disease behavior and treatment remain.
  • Real-world observational studies provide valuable insights.

Purpose of the Study:

  • Review observational studies from the last two years.
  • Compare escalation vs. induction treatment strategies in MS.
  • Assess treatment effectiveness in pediatric-onset and late-onset MS.
  • Identify the clinical phenotype of secondary progressive MS (SPMS).

Main Methods:

  • Analysis of large MS registries and databases.
  • Advanced statistical methods applied to real-world data.
  • Focus on observational studies published within the last two years.

Main Results:

  • Early initiation of high-efficacy disease-modifying therapies (DMTs) is recommended to prevent neurological disability.
  • Pediatric MS patients show substantial benefits from early treatment.
  • Sustained DMT exposure may improve outcomes in late-onset MS.
  • Data-driven definitions are more accurate for identifying SPMS transition than clinical judgment.

Conclusions:

  • Real-world evidence from registries aids in MS diagnostics and treatment decisions.
  • Early and sustained treatment strategies are crucial for managing MS.
  • Data-driven approaches enhance the accuracy of SPMS identification.